Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Mallinckrodt Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring that such goods meet safety, quality, and efficacy standards. This Act was introduced to address the need for a comprehensive framework governing the importation, manufacture, supply, and advertising of therapeutic goods within Australia. The Act is administered by the Therapeutic Goods Administration (TGA), which is part of the Department of Health, and aims to protect public health by regulating therapeutic goods. Under sections 14 and 14A, the Act allows for consent to be granted for the importation and supply of therapeutic goods that do not fully conform to certain regulatory requirements, provided that such consents are granted subject to specific conditions designed to mitigate any potential risks. In the case of Mallinckrodt Australia Pty Ltd, consent was granted for the importation and supply of injection composite packs (ULTRATAG RBC) that did not meet labelling requirements due to the inclusion of the previous sponsor's details. This consent was subject to conditions ensuring that no further changes were made and that any queries or complaints were appropriately referred.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, with sections 14 and 14A providing a mechanism for the importation and supply of goods that do not fully conform to the regulatory requirements. Specifically, this Act applies to entities such as Mallinckrodt Australia Pty Ltd, which have applied for and received consent to import and supply goods that do not comply with certain labelling requirements. The Act's application extends to ensuring that therapeutic goods are safe and of acceptable quality, but it also provides a framework for exceptions where strict compliance may be temporarily waived. The consent provided under these sections is geographically applicable across Australia and is subject to specific conditions to mitigate any potential risks to public health or safety. In this instance, the consent allows for the importation and supply of injection composite packs that do not bear the previous sponsor's details on the labels, provided the incoming sponsor has arrangements to handle any queries or complaints. The consent is effective for a limited period, ensuring that the non-compliance is temporary and closely monitored.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 provide a framework for granting consent to import and supply therapeutic goods that do not fully comply with certain regulatory requirements. In this particular case (paragraphs 14 and 14A Notice On 2 September 2015), a delegate of the Secretary of the Department of Health has granted consent to Mallinckrodt Australia Pty Ltd for the importation and supply of injection composite packs (ULTRATAG RBC) [AUST R 47860]. This consent was provided due to a non-conformance issue with the labelling requirements specified in Therapeutic Goods Order No. 69, where the name and address of the previous sponsor were included on the labels. The consent is effective for a period of 12 months, from 14 September 2015 to 13 September 2016, and is subject to certain conditions that need to be fulfilled during this period. The Act imposes specific obligations on the parties involved. Firstly, Mallinckrodt Australia Pty Ltd must ensure that the labels in question are the ones that were approved and provided with the application letter. Secondly, it is required to have arrangements in place with Mallinckrodt, the outgoing sponsor, to refer any queries or complaints concerning the products to Landauer, the incoming sponsor. Lastly, it must confirm that no other changes have been made to the product beyond what has been specified in the consent. Failure to comply with the conditions set forth in the consent may lead to various consequences. While the Therapeutic Goods Act 1989 does not explicitly outline specific offences, penalties, or civil/criminal consequences for breaching the terms of this consent, breaches of other sections within the Act can result in severe penalties. For instance, breaches of the Act can lead to civil penalties of up to $1,260,000 for corporations and $252,000 for individuals, as well as criminal penalties including fines and imprisonment. It is essential for the parties involved to adhere to the conditions outlined in the consent to avoid potential legal consequences.